Introduction {#Sec1}
============

Chemotherapy-induced nausea and vomiting (CINV) remains a critical clinical challenge, with important deleterious effects on patients' quality of life (QoL). Uncontrolled CINV can lead to anorexia, malnutrition, dehydration, and metabolic imbalances. Moreover, poor CINV control in previous cycles may result in anticipatory CINV. Potential consequences of uncontrolled CINV are poor treatment compliance and even discontinuation of potentially beneficial chemotherapy \[[@CR1]--[@CR5]\]. Advances in antiemetic therapies have greatly reduced CINV incidence, and vomiting can be prevented in the majority of cancer patients \[[@CR6], [@CR7]\]. While improvements have also occurred in the prevention of nausea, this control is markedly less than with vomiting and can be particularly prominent in delayed nausea during the course of chemotherapy \[[@CR1], [@CR8]--[@CR13]\]. Prevention of nausea has become a top priority in antiemetic clinical research, and many have considered that this should be the primary endpoint in clinical trials.

Antiemetic guidelines categorize chemotherapeutic agents based on the frequency with which patients experience acute emesis (0--24 h after chemotherapy) in the absence of antiemetic prophylaxis into four CINV risk levels: highly emetogenic chemotherapy (HEC: by non-anthracycline--cyclophosphamide (non-AC) and AC--HEC), moderately emetogenic chemotherapy (MEC; carboplatin and others), low emetogenic chemotherapy, and minimally emetogenic chemotherapy. Antiemetics with highest therapeutic index are 5-hydroxytryptamine-3 (5-HT~3~) receptor antagonists (RAs), NK~1~RAs, and corticosteroids, especially dexamethasone \[[@CR6], [@CR11], [@CR14]\].

The NK~1~RA family of antiemetics acts by blocking substance P activity at NK~1~ receptors in the brain, offering a mechanism of action distinct from and complementary to 5-HT~3~RAs. NK~1~RAs were rapidly incorporated into international antiemetic guidelines and are currently recommended for prevention of CINV induced by non-AC-- and AC--HEC \[[@CR1], [@CR10], [@CR15]--[@CR21]\] or carboplatin-based MEC \[[@CR21]\]. The two newest members of this class, netupitant (in a fixed combination with palonosetron as NEPA) and rolapitant have recently become available \[[@CR22]--[@CR24]\] and are also included in antiemetic guidelines \[[@CR1], [@CR10], [@CR21]\].

This review focuses on prevention of CIN and the role of NK~1~RAs in its management.

Neuropharmacology of nausea {#Sec2}
---------------------------

Nausea is defined as an epigastric discomfort or unpleasant awareness of being on the verge of vomiting. Vomiting is the retrograde expulsion of gastric contents through the mouth \[[@CR25]\].

Nausea and vomiting often are clinically associated; however, nausea can occur alone or with other symptoms such as dyspepsia. Nausea is a subjective sensation, while vomiting is an objective reflex that can be easily measured \[[@CR26]\].

The neuropharmacology of nausea and vomiting is also distinct and, particularly in the case of nausea, not well understood. In contrast to vomiting, nausea has been shown to require conscious awareness and cortical function \[[@CR27]\]. Additionally, some studies have demonstrated that nausea is accompanied by an increase in vasopressin and oxytocin levels \[[@CR28]\]. Elevations in plasma cortisol, β-endorphin, epinephrine, and norepinephrine concentrations and alterations in gastric myoelectric activity also occurred in subjects who developed nausea in motion sickness models \[[@CR29], [@CR30]\].

The aprepitant--ondansetron--dexamethasone regimen, although significantly superior in the control of chemotherapy-induced vomiting, was not superior in the control of overall nausea when compared to ondansetron--dexamethasone \[[@CR15], [@CR17]\]. This observation suggests that nausea and vomiting may occur through distinct, although shared, pharmacologic mechanisms, and that better protection against nausea likely requires targeting receptors other than 5-HT~3~ and NK~1~ \[[@CR31]\]. Muscarinic, histaminic, and adrenergic receptors, involved in the mechanism of vomiting and nausea unrelated to chemotherapy \[[@CR32]\], are potential candidates. Identification and characterization of brain mechanisms leading to nausea await further research.

Methodology and data gaps in nausea assessment in clinical trials {#Sec3}
-----------------------------------------------------------------

Assessment of nausea is challenging because of its subjective nature, and methods for its clinical evaluation have not evolved substantially over the past 30 years \[[@CR33]\]. Until recently, nausea has not been the primary efficacy endpoint in antiemetic clinical studies. Instead, nausea has been evaluated as part of the composite term "complete response" (CR) (no emesis and no rescue medication), where "no need for rescue" serves as a surrogate marker for no nausea or only mild nausea. Nausea has also been assessed as a secondary efficacy endpoint in most studies, where nausea duration and intensity are commonly reported as "no nausea" (visual analog scale (VAS) \<5 mm) and/or "no significant nausea" (NSN; VAS \<25 mm), measured daily and overall 0--120 h from the start of chemotherapy, and for different periods of the day. Additionally, the Functional Living Index-Emesis (FLIE) questionnaire collects patient-reported information on different aspects of nausea and vomiting that might impact patients' daily life. Because of the subjective nature of nausea, the design of clinical studies with matching identical placebo medication in the control arm is of special importance.

Correctly reporting the onset of nausea (as acute, delayed, or overall) is also of great relevance. Of special concern is the management of delayed nausea, which has a higher incidence \[[@CR34]--[@CR37]\] and greater severity than acute nausea, and is less responsive to treatment \[[@CR36], [@CR38]\]. The subjective nature of nausea and communication barriers between healthcare professionals and patients may result in nausea underreporting by patients and in underestimation of its incidence, especially during the delayed phase, by healthcare professionals \[[@CR37], [@CR39], [@CR40]\]. Subjective toxicities are more likely to be underreported by physicians in oncology clinical trials \[[@CR41]\]. For nausea, an underreporting of 40.7% has been described in this large pooled database (*N* = 1090) of three randomized trials \[[@CR41]\].

NK~1~RAs in nausea prevention {#Sec4}
-----------------------------

NK~1~RAs bring significant improvement in CINV control \[[@CR6], [@CR7], [@CR32], [@CR42]\]; however, their role in nausea prophylaxis is less established. Here, we review clinical data on nausea-related outcomes from selected NK~1~RA trials in which nausea was evaluated either as part of CR or as a secondary endpoint (Table [1](#Tab1){ref-type="table"}) \[[@CR15]--[@CR18], [@CR43]--[@CR52]\].Table 1Summary of studies for the prevention of CIN in patients treated with NK~1~RAs in phase III clinical trials^a^ReferencePatients randomizedChemotherapy regimenAntiemetic prophylaxisProportion of patients with no significant nausea (%)AcuteDelayedOverall*Aprepitant*Warr \[[@CR17]\]866AC-HECAPR + OND + DEX vs. PBO + OND + DEXNANA61 vs. 56*No nausea* (*%*) 33 vs. 33Rapoport \[[@CR18]\]848AC-HEC/MECAPR + OND + DEX vs. PBO + OND + DEXNANA73.6 vs. 66.4\*Hesketh \[[@CR15]\]530HECAPR + OND + DEX vs. PBO + OND + DEX90.6 vs. 86.575.3 vs. 68.573.2 vs. 66.0Poli-Bigelli \[[@CR16]\]569HECAPR + OND + DEX vs. PBO + OND + DEXNA73 vs. 6571 vs. 64*No nausea* (*%*) 52.7 vs. 39.9\*\**No nausea* (*%*) 48.8 vs. 38.8\*Schmoll \[[@CR45]\]489HECAPR + OND + DEX vs. PBO + OND + DEX92.1 vs. 89.575.9 vs. 72.173.1 vs. 69.7*Fosaprepitant*Grunberg \[[@CR46]\]2322HECFOS + OND + DEX vs. APR + OND + DEXNANA70.1 vs. 70.4*No nausea* (*%*) 53.0 vs. 50.9Weinstein \[[@CR47]\]1015MECFOS + OND + DEX (D1) vs. PBO + OND + DEX (D1) followed by OND (D2--3)83.1 vs. 78.3\**No nausea* (*%*) 65.3 vs. 61.6*Aprepitant* ***/*** *fosaprepitant in delayed nausea*Roila \[[@CR48]\]580AC-HECBoth arms APR + PAL + DEX (D1) followed by APR once-daily (D2--3) + PBO once daily (evenings) vs. DEX twice daily (D2--3)36.3 vs. 32.656.8 vs. 63.7NA*No nausea* (*%*) 53.6 vs. 52.0*No nausea* (*%*) 43.9 vs. 49.1Roila \[[@CR49]\]284HECBoth arms APR + PAL + DEX (D1) followed by APR (D2--3) + DEX (D2--4) vs. MTC (D2--4) + DEX (D2--4)87.8 vs. 89.877.6 vs. 81.0NA*No nausea* (*%*) 80.3 vs. 86.9*No nausea* (*%*) 71.4 vs. 73*Rolapitant*Schwartzberg \[[@CR44]\]1369AC--HEC/MECD1: ROL + GRAN + DEX vs. PBO + GRAN + DEX D2--3: GRAN82 vs. 8573 vs. 6971 vs. 67*No nausea* (*%*) 65 vs. 66*No nausea* (*%*) 48 vs. 45*No nausea* (*%*) 45 vs. 42Rapoport \[[@CR43]\]532 (Study 1)HECD1: ROL + GRAN + DEX vs. PBO + GRAN + DEX D2--4: DEX86 vs. 79\*73 vs. 65\*72 vs. 63\**No nausea* (*%*) 68 vs. 61*No nausea* (*%*) 53 vs. 42\*\**No nausea* (*%*) 50 vs. 39\*Rapoport \[[@CR43]\]555 (Study 2)HECD1: ROL + GRAN + DEX vs. PBO + GRAN + DEX D2--4: DEX90 vs. 8675 vs. 6973 vs. 68*No nausea* (*%*) 73 vs. 68*No nausea* (*%*) 58 vs. 47\*\**No nausea* (*%*) 55 vs. 44\*\****NEPA***Aapro \[[@CR50]\]1455AC-HECNEPA + DEX (D1) vs. PAL + DEX (D1)87.3 vs. 87.976.9 vs. 71.3\*74.6 vs. 69.1\*Gralla^b^ \[[@CR51]\]413HEC/MECNEPA + DEX^c^ + PBO vs. APR + PAL + DEX^c^NANA84.1--92.3 vs. 80.8--86.5 cycles (1--6)Hesketh^d^ \[[@CR52]\]694HECNEPA~300~ (NETU~300~ + PAL) + DEX (D1--4) (*N* = 143) vs. PAL + DEX (D1--4) + PBO (*N* = 136)98.5 vs. 93.4\*90.4 vs. 80.9\*89.6 vs. 79.4\**AC* anthracycline plus cyclophosphamide, *APR* aprepitant, *CIN* chemotherapy-induced nausea, *D* day, *DEX* dexamethasone, *FOS* fosaprepitant, *GRAN* granisetron, *HEC* highly emetogenic chemotherapy, *MEC* moderately emetogenic chemotherapy, *MTC* metoclopramide, *NA* not available, *NEPA* netupitant (300 mg) plus palonosetron (0.5 mg), *NETU* netupitant, *NK* ~*1*~ neurokinin-1, *OND* ondansetron, *PAL* palonosetron, *PBO* placebo, *RA* receptor antagonist, *ROL* rolapitant^a^Nausea was not the primary endpoint of these phase III trials^b^No formal testing was performed for between-group comparisons^c^Dexamethasone was administered on days 1--4 in patients receiving HEC and on day 1 in patients receiving MEC^d^Phase II pivotal study. NEPA~100~/NEPA~200~/NEPA~300~ + DEX doses were analyzed. Only data from NEPA~300~ + DEX vs. PAL + DEX are presented\**p* ≤ 0.05;\*\**p* ≤ 0.01

### Aprepitant/fosaprepitant {#Sec5}

#### The addition of aprepitant/fosaprepitant to 5-HT~3~RA and dexamethasone {#FPar1}

Aprepitant was the first NK~1~RA approved by the Food and Drug Administration (FDA) and European Medicines Agency (EMA), in 2003. Next, fosaprepitant, an intravenous water-soluble phosphoryl prodrug of aprepitant, was approved in 2008. Fosaprepitant is rapidly converted to the active form (aprepitant) and has demonstrated bioequivalence and non-inferiority to aprepitant \[[@CR46], [@CR53]\].

Three phase III trials have compared the aprepitant--ondansetron--dexamethasone combination with ondansetron--dexamethasone alone in cisplatin-based HEC-treated patients \[[@CR15], [@CR16], [@CR45]\]. No significant differences were observed in frequency of NSN in the overall period or in the acute and delayed periods (where reported) in these studies.

The contribution of aprepitant to the standard ondansetron--dexamethasone regimen was also analyzed in breast cancer patients treated with AC--HEC \[[@CR17]\]. In this study, no significant differences were observed between the aprepitant and standard-treatment arms in percentage of patients reporting overall "no nausea" and NSN. Finally, a study by Rapoport et al. explored use of the aprepitant regimen in patients receiving AC and various MEC regimens. The percentage of patients reporting NSN during the overall period was significantly higher in the aprepitant than in the control group (*p* \< 0.05) \[[@CR18]\]. No separate analyses were performed for acute and delayed nausea in these studies \[[@CR17], [@CR18]\].

Recently, fosaprepitant was evaluated in a phase III trial that compared a single-day, fosaprepitant-containing antiemetic triplet regimen to a standard 3-day 5-HT~3~RA--dexamethasone regimen in patients treated with MEC \[[@CR47]\]. Randomized patients received single-dose (1) fosaprepitant in combination with ondansetron--dexamethasone or (2) ondansetron--dexamethasone on day 1. On days 2 and 3, ondansetron was administered only to patients in the control group. Overall, the proportion of patients with NSN was greater in the fosaprepitant group (*p* = 0.026), but no significant differences were observed in the rates of no nausea (*p* = 0.156).

Finally, aprepitant/fosaprepitant have been evaluated in a phase III study in oxaliplatin-treated patients with colorectal cancer. Women treated with aprepitant/fosaprepitant achieved significantly higher rates of no nausea and complete protection, compared to women in the control group, suggesting a specific benefit of aprepitant treatment in the female gender \[[@CR54]\].

In conclusion, no consistent superiority in the control of nausea after HEC or MEC was observed with the addition of aprepitant over the ondansetron--dexamethasone combination. This finding prodded antiemetic research to focus on nausea control.

#### Aprepitant/fosaprepitant compared with other agents {#FPar2}

The efficacy between aprepitant and prochlorperazine treatment was compared in patients receiving anthracyclines and/or platinum agents. Treatment with aprepitant was as effective as prochlorperazine, both in combination with palonosetron--dexamethasone, in delayed nausea control (*p* = 0.557) \[[@CR55]\].

Olanzapine, an atypical antipsychotic, is a potent dopaminergic and serotonergic RA, and it also binds to adrenergic, histaminergic, and muscarinic receptors \[[@CR56]\]. A phase III randomized trial compared aprepitant to olanzapine (10 mg orally, on day 1 pre-chemotherapy, and days 2--4 post-chemotherapy) both combined with palonosetron--dexamethasone, in patients receiving cisplatin or AC \[[@CR57]\]. The percentage of patients without nausea (no nausea = 0, scale 0--10, MD Anderson Symptom Inventory) was greater in the olanzapine group than in the aprepitant group during the delayed and overall periods. Recently, a randomized, double-blind phase III study compared the efficacy of olanzapine (same dosing regimen) and fosaprepitant, both in combination with palonosetron--dexamethasone, in patients receiving concurrent local radiation and cisplatin-based HEC. Nausea control was one of the main outcome measures. No nausea (0, scale 0--10, VAS) rates were significantly higher in patients receiving olanzapine compared to fosaprepitant during the delayed and overall periods (*p* \< 0.01) \[[@CR58]\]. The superiority of olanzapine may provide new insight into the pathophysiology of CIN. It is possible that receptors other than 5-HT~3~ and NK~1~ may be important for nausea control \[[@CR32], [@CR59]\]. The action of olanzapine on dopaminergic, histaminic, and muscarinic receptors provides a potential explanation for its activity in the control of nausea, especially delayed nausea. Olanzapine is also an effective antiemetic for treatment of chronic chemotherapy-unrelated nausea in palliative care \[[@CR60]\]. The efficacy of olanzapine on CIN was recently recognized by the Multinational Association of Supportive Care in Cancer and European Society for Medical Oncology (MASCC/ESMO) and the National Comprehensive Cancer Network (NCCN) guidelines \[[@CR1], [@CR21]\].

A summary of the above mentioned studies is presented in Table [2](#Tab2){ref-type="table"} \[[@CR55], [@CR57], [@CR58]\].Table 2Summary of studies for the prevention of CIN with antiemetic regimens based on aprepitant/fosaprepitant compared to other agentsReferencePatients randomizedChemotherapy regimenAntiemetic prophylaxisProportion of patients with no nausea (%)AcuteDelayedOverallNavari \[[@CR57]\]251HEC (AC/non-AC)APR + PAL + DEX vs. OLZ + PAL + DEX87 vs. 8738 vs. 69\*38 vs. 69\*Navari \[[@CR58]\]109HEC (+ radiotherapy)FOS + PAL + DEX vs. OLZ + PAL + DEX77 vs. 8641 vs. 7141 vs. 71Roscoe \[[@CR55]\]513HEC/MECBoth arms PAL + DEX (D1) followed by DEX (D2--3), and: APR once daily (D2--3) + PBO twice daily vs. PROC three times daily (D2--3)NANo significant differenceNA*AC* anthracycline plus cyclophosphamide, *APR* aprepitant, *CIN* chemotherapy-induced nausea, *DEX* dexamethasone, *FOS* fosaprepitant, *HEC* highly emetogenic chemotherapy, *MEC* moderately emetogenic chemotherapy, *NA* not available, *OLZ* olanzapine, *PAL* palonosetron, *PROC* prochlorperazine\**p* \< 0.01

#### Aprepitant in delayed nausea prevention {#FPar3}

Aprepitant was compared to dexamethasone for prevention of delayed emesis in 580 breast cancer patients receiving AC \[[@CR48]\]. All patients were treated with an aprepitant--palonosetron--dexamethasone regimen before chemotherapy, and then randomized to receive oral dexamethasone or aprepitant on days 2--3. During the delayed phase, no significant differences were observed in rates of no nausea (*p* = 0.24) and NSN (*p* = 0.10) between aprepitant and dexamethasone treatment, respectively (Table [1](#Tab1){ref-type="table"}) \[[@CR15]--[@CR18], [@CR43]--[@CR52]\]. Maximum nausea severity and nausea duration were also comparable between the two groups \[[@CR48]\]. Non-inferiority of dexamethasone was recently recognized by MASCC/ESMO guidelines following AC--HEC \[[@CR21]\].

In another study, 284 evaluable patients receiving cisplatin-based HEC were treated with aprepitant--palonosetron--dexamethasone before cisplatin-based chemotherapy \[[@CR49]\]. Patients were then randomly assigned to treatment with aprepitant on days 2--3 or metoclopramide on days 2--4 (plus dexamethasone on days 2--4 in both groups). The proportion of patients with no nausea (*p* = 0.80) and NSN (*p* = 0.56) in the delayed phase was similar in both arms, and no significant differences regarding maximum severity of nausea or nausea duration were observed. Non-inferiority of metoclopramide--dexamethasone was recently recognized by MASCC/ESMO guidelines following non-AC--HEC \[[@CR21]\].

### Rolapitant {#Sec6}

The novel NK~1~RA rolapitant received FDA approval in 2015 for delayed CINV prevention \[[@CR24]\]. Rolapitant has a long half-life (approximately 180 h) and, consistent with its pharmacokinetic profile, has been shown to provide CINV protection for the overall risk period after chemotherapy \[[@CR43], [@CR44]\]. The benefit of adding rolapitant to a 5-HT~3~RA--dexamethasone regimen was evaluated in patients receiving MEC and HEC. In a phase III trial, 1369 patients received (1) rolapitant in combination with granisetron--dexamethasone or (2) placebo in combination with granisetron--dexamethasone, before AC--HEC or MEC \[[@CR44]\]. Granisetron was continued on days 2--3 in both arms, not in line with current guidelines' recommendations. The two groups presented a similar percentage of patients with NSN during the acute (*p =* 0.1927), delayed (*p =* 0.1944), and overall (*p =* 0.1182) phases. Likewise, there were no significant differences in the no nausea rates between the two groups in all treatment phases: acute (*p =* 0.6932), delayed (*p =* 0.2013), or overall (*p =* 0.2193). In conclusion, in patients receiving AC--HEC or MEC, the addition of rolapitant did not offer improvement in nausea control over granisetron--dexamethasone.

A similar rolapitant-based regimen was assessed in two phase III trials (HEC-1 and HEC-2) in a total of 1087 patients receiving cisplatin-based HEC \[[@CR43]\]. Patients in both studies received (1) rolapitant plus granisetron--dexamethasone or (2) placebo in combination with granisetron--dexamethasone before HEC and daily dexamethasone on days 2--4 in both groups. In the analysis of the individual studies, only study HEC-1 showed significantly higher NSN rates in all phases for the rolapitant group. Additionally, rates of no nausea in the acute phase were not significantly different between rolapitant and the control group in either study \[[@CR43]\] (Table [1](#Tab1){ref-type="table"}) \[[@CR15]--[@CR18], [@CR43]--[@CR52]\]. In the pooled analysis of both studies, rolapitant treatment resulted in significantly superior rates of NSN compared to control during the acute (88 vs. 83%; *p =* 0.0090), delayed (74 vs. 67%; *p =* 0.0108), and overall (72 vs. 65%; *p =* 0.0174) periods. Also, in the pooled study analysis, a significantly greater proportion of patients in the rolapitant group had no nausea in the acute (70 vs. 64%; *p =* 0.0304), delayed (56 vs. 44%, *p =* 0.0002), and overall (52 vs. 42%, *p =* 0.0004) phases. Due to discrepancies between the studies, no clear conclusions can be drawn regarding the clinical significance of rolapitant on nausea induced by HEC.

### NEPA: the first oral combination antiemetic {#Sec7}

NEPA is a single, oral, fixed-combination capsule composed of the novel NK~1~RA netupitant (300 mg) plus the second-generation 5-HT~3~RA palonosetron (0.5 mg). Netupitant has a half-life of 90 h and high binding affinity for the NK~1~ receptor. Palonosetron presents 5-HT~3~ receptor allosteric binding with positive cooperativity, can trigger 5-HT~3~ receptor internalization, and can inhibit 5-HT~3~/NK~1~ receptor cross-talk \[[@CR61]\]. Therefore, NEPA is the combination of two highly effective antiemetic agents that antagonizes two key neurotransmitters involved in the pathophysiology of CINV (substance P and serotonin). The efficacy and safety of NEPA were demonstrated in three pivotal trials \[[@CR50]--[@CR52]\].

In the randomized phase II pivotal study of 694 patients receiving cisplatin-based HEC, three different doses of NEPA (netupitant 100, 200, or 300 mg, each with palonosetron 0.50 mg) were compared with palonosetron alone; all patients also received dexamethasone \[[@CR52]\]. Significantly lower rates of NSN were reported in the NEPA (300 mg) group compared with the group that received oral palonosetron for the acute (*p* ≤ 0.05), delayed (*p* ≤ 0.01), and overall (*p* ≤ 0.05) phases \[[@CR52], [@CR62]\] (Fig. [1](#Fig1){ref-type="fig"}a) \[[@CR62]\]. The efficacy of NEPA plus dexamethasone on day 1 was compared with oral palonosetron and dexamethasone in a phase III trial with 1455 patients receiving AC \[[@CR50]\]. Treatment with NEPA was associated with a significant reduction in the rate of NSN in the delayed and overall phases (*p* = 0.014 and *p =* 0.020) compared with oral palonosetron \[[@CR50]\] (Fig. [1](#Fig1){ref-type="fig"}b) \[[@CR62]\]. Superiority of NEPA--dexamethasone in nausea control was maintained over 4 cycles of AC chemotherapy, with overall NSN rates ranging from 75 to 80% (Fig. [1](#Fig1){ref-type="fig"}c) \[[@CR62]\]. Therefore, in patients receiving cisplatin- or AC-based HEC, the NEPA--dexamethasone regimen offers significant improvement in nausea control over palonosetron--dexamethasone.Fig. 1**a** No significant nausea after cycle 1 in patients receiving HEC; **b** no significant nausea after cycle 1 in patients receiving AC; **c** no significant nausea rates (overall 0--120 h) over cycles 1--4 in patients receiving AC; **d** no significant nausea rates (overall 0--120 h) over cycles 1--6 in patients receiving HEC or non-AC MEC. *5-HT* ~*3*~ 5-hydroxytryptamine-3, *AC* anthracycline and cyclophosphamide, *APR* aprepitant, *DEX* dexamethasone, *HEC* highly emetogenic chemotherapy, *MEC* moderately emetogenic chemotherapy, *NEPA* netupitant (300 mg) plus palonosetron (0.5 mg), *NK* ~*1*~ neurokinin-1, *PALO* palonosetron, *RA* receptor antagonist, *VAS* visual analog scale \[Bošnjak S, Schwartzberg LS, Rizzi G, Borroni ME (2014) Evaluation of nausea control with NEPA, a novel oral combination antiemetic. J Clin Oncol 32(Suppl): abstract 169\]

A phase III trial was conducted in 413 patients to evaluate the safety of NEPA, and also to determine NEPA efficacy over multiple cycles of HEC (non-AC) or MEC treatment \[[@CR51]\]. Patients were randomized (3:1) to either NEPA--dexamethasone or aprepitant--palonosetron--dexamethasone. The aprepitant regimen was included to help interpret any unexpected safety finding that might have emerged in the NEPA group. Efficacy of NEPA--dexamethasone on nausea control was maintained over 6 cycles, with overall NSN rates between 84 and 92% (Fig. [1](#Fig1){ref-type="fig"}d) \[[@CR62]\].

Finally, in population subanalyses on gynecologic (*n* = 130) or lung (*n* = 231) cancer patients, NEPA treatment achieved high NSN rates after cisplatin- or carboplatin-based chemotherapy \[[@CR63], [@CR64]\]. In breast cancer patients (*n* = 1460), NEPA--dexamethasone was significantly superior to palonosetron--dexamethasone in overall NSN and across four chemotherapy cycles \[[@CR65]\]. Of note, gynecologic and female breast cancer patients represent high-risk populations for CINV, since female gender is a well-known risk factor.

Additional factors to consider when selecting NK~1~RA for CIN control {#Sec8}
---------------------------------------------------------------------

### The safety of NK~1~RAs {#Sec9}

Generally, NK~1~RAs present favorable tolerability with a safety profile similar to non--NK~1~RA-based regimens and mostly with mild and infrequent adverse events (AEs). A meta-analysis reported hiccups and fatigue/asthenia as the most common AEs associated with aprepitant/fosaprepitant, as well as increased incidence of severe infections \[[@CR19]\]. Fosaprepitant administration has also been associated with infusion-site reactions \[[@CR66]\]. For rolapitant, the most frequent AEs include fatigue, constipation, headache, hiccups, and dyspepsia, with neutropenia the most common grade 3--4 AE \[[@CR43], [@CR44]\]. NEPA has shown a similar safety profile to palonosetron, with headache and constipation as the most frequent AEs, and no evidence for cardiac safety concerns \[[@CR51], [@CR67]\]. The most frequent toxicities associated with metoclopramide comprise sedation, diarrhea, and extrapyramidal reactions \[[@CR68]\]. Recently, the EMA has recommended a restriction on the dose and duration of metoclopramide use, to minimize the risk of potentially serious neurologic AEs \[[@CR69]\].

Potential interactions between NK~1~RAs and other chemotherapy agents should also be considered. Both aprepitant and netupitant can inhibit cytochrome P-450 isoenzyme 3A4 (CYP3A4), and a reduced dose of dexamethasone (CYP3A4 substrate) should be administered with aprepitant and NEPA. Additionally, aprepitant is a CYP3A4 inducer and has the potential to increase ifosfamide-mediated neurotoxicity \[[@CR70]\]. No increased toxicities have been reported to date related to NEPA interaction with chemotherapeutic agents \[[@CR71], [@CR72]\]. Rolapitant does not affect CYP3A4, and dexamethasone dose adjustments are not required when they are coadministered \[[@CR24]\]. However, rolapitant is a CYP2D6 inhibitor and should not be used concomitantly with CYP2D6 substrates with a narrow therapeutic index \[[@CR24]\]. Of note, CYP2D6 participates in the metabolism of all 5-HT~3~RAs except granisetron \[[@CR73], [@CR74]\], which may limit the choice of partner 5-HT~3~RA.

### Schedule and convenience of administration of different NK~1~RAs and implications for patient compliance {#Sec10}

The use of oral antiemetics with increased half-life, such as NEPA and rolapitant, which can be administered orally once per chemotherapy cycle, may be especially beneficial, whereas aprepitant follows a 3-day schedule \[[@CR15], [@CR43], [@CR44], [@CR50]--[@CR52]\]. Additionally, NEPA as a combination agent includes the NK~1~RA and 5-HT~3~RA in a single capsule, while both aprepitant- and rolapitant-based regimens require additional administration of the 5-HT~3~RA separately. Adopting strategies that simplify antiemetic treatment may potentially ensure both antiemetic and chemotherapy compliance by patients.

### The choice of 5-HT~3~RA {#Sec11}

The potential role of palonosetron, and its contribution to CIN prevention, when combined with an NK~1~RA requires further consideration. A pooled analysis showed that in patients receiving intravenous palonosetron prophylaxis before HEC or MEC, no nausea rates were numerically higher compared with first-generation 5-HT~3~RAs in the delayed and overall phases, and that patients experienced significantly less-severe nausea (delayed, *p* = 0.0002; overall, *p =* 0.011) \[[@CR12]\]. These effects may be explained by the pharmacologically and clinically distinct properties of palonosetron as compared to first-generation 5-HT~3~RAs \[[@CR75]\]. During its clinical development, NEPA was superior to palonosetron in the control of overall and delayed nausea (measured by NSN) \[[@CR50], [@CR52]\].

### International guidelines recommendations {#Sec12}

Recommendations for CINV prophylaxis have been defined in the MASCC/ESMO \[[@CR21]\], American Society of Clinical Oncology (ASCO) \[[@CR10]\], and NCCN \[[@CR1]\] guidelines. These recommendations are based on evidence from clinical studies in which the primary efficacy endpoint was most commonly CR and not a nausea-related outcome. CINV prophylaxis with the NK~1~RA--5-HT~3~RA--dexamethasone triplet combination is recommended for patients receiving AC and non-AC HEC by all three guidelines and for patients receiving carboplatin-based chemotherapy by MASCC/ESMO guidelines \[[@CR21]\]. In MEC-treated patients, the NK~1~RA--5-HT~3~RA--dexamethasone combination is also recommended for selected patients in accordance with clinician's decision by ASCO guidelines \[[@CR10]\], and by NCCN guidelines in patients with further high-risk factors, or if previous 5-HT~3~RA--dexamethasone treatment has failed \[[@CR1]\].

Regarding the choice of NK~1~RA, all four NK~1~RAs were gradually incorporated into international guidelines in a timely manner following their approval in the respective geographic regions. Currently, aprepitant/fosaprepitant and NEPA are recommended by all three guidelines \[[@CR1], [@CR10], [@CR21]\], and rolapitant is included in recommendations by MASCC/ESMO and NCCN \[[@CR1], [@CR21]\].

Future directions {#Sec13}
-----------------

Nausea control has become the top priority of current antiemetic research, to reach the final goal of "no nausea/no vomiting" after anticancer treatment. Progress in understanding the pathophysiology of nausea, and the design of clinical trials with nausea as primary efficacy endpoint should help determine the most effective antiemetic combination for nausea prevention.

The accurate measurement of nausea, both in clinical trials and in daily practice, remains a priority. While VAS and categorical scales (as documented in the MASCC antiemesis tool (MAT) \[[@CR25]\]) may provide reproducible and useful measurements, results are often documented inconsistently, and NSN or no nausea are not reported at times. We would advise that the VAS actual scores be reported and analyzed, rather than be categorized. These additional measures should improve the consistency of the data and could assist in statistical review. Reporting exact VAS scores for nausea and for individual items on the nausea domain of the FLIE questionnaire in all patients (including those for whom treatment has failed) would also aid in understanding the effect of antiemetics on patients' QoL as suggested by Andrews \[[@CR76]\]. Furthermore, strategies to improve patient-healthcare professional communication and use of tools that incorporate patient-reported outcomes to evaluate toxicity in cancer clinical trials may help prevent underreporting of nausea \[[@CR41]\].

The benefit of adding olanzapine to a triplet aprepitant/fosaprepitant--5-HT~3~RA--dexamethasone regimen for the control of nausea has been evaluated in a phase III study in 380 patients receiving cisplatin- or AC-based HEC \[[@CR77]\]. Nausea prophylaxis was the primary endpoint. The proportion of patients with no nausea (0, scale 0--10, VAS) was significantly greater in the olanzapine group during the acute (74 vs. 45%; *p* = 0.002), delayed (42 vs. 25%; *p* = 0.002), and overall (37 vs. 22%; *p* = 0.002) periods. Olanzapine (10 mg daily for 4 days) was associated with transient but significantly increased sedation \[[@CR77]\]. No grade 3--4 olanzapine-related AEs have been reported in CINV clinical trials \[[@CR32], [@CR59], [@CR77]\]. The addition of olanzapine to aprepitant-/fosaprepitant-containing antiemetic regimens can improve CINV control without substantial added costs \[[@CR78]\]. In addition, the effectiveness of olanzapine was comparable to aprepitant for the prevention of CINV \[[@CR57]\] and provides a more cost-effective alternative to aprepitant-based regimens.

Further efforts should be made to better define the overall potential for CIN in a given patient, including anticancer drug-, patient-, and disease-related factors \[[@CR79], [@CR80]\]. Moreover, the efficacy of guideline-recommended antiemetics in real-life situations (outside of controlled conditions of clinical trials, in patients receiving medications or interventions known to induce nausea, for example, opioids) should be analyzed. Currently, a need to improve guideline adherence by clinicians and compliance with antiemetic regimens by patients exists. Simplification of antiemetic regimens with agents that are administered orally once per chemotherapy cycle, such as rolapitant (as single-agent NK~1~RA) or NEPA (as a fixed combination of an NK~1~RA and a 5-HT~3~RA) may contribute to this improvement. While the addition of olanzapine to the triple combination has proven to improve CINV prophylaxis \[[@CR77]\], compliance with this complex four-drug antiemetic regimen and its feasibility outside of clinical trials needs to be evaluated.
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